How to Address Uncertainty in Health Economic Discrete-Event Simulation Models: An Illustration for Chronic Obstructive Pulmonary Disease
暂无分享,去创建一个
Isaac Corro Ramos | Maureen P M H Rutten-van Mölken | Martine Hoogendoorn | M. Hoogendoorn | M. R. Rutten-van Mölken | I. Corro Ramos
[1] K. Rabe,et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. , 2011, The New England journal of medicine.
[2] N. Freemantle,et al. Development and validation of the Economic Assessment of Glycemic Control and Long-Term Effects of diabetes (EAGLE) model. , 2006, Diabetes technology & therapeutics.
[3] I. Buchan,et al. Calculating when elective abdominal aortic aneurysm repair improves survival for individual patients: development of the Aneurysm Repair Decision Aid and economic evaluation. , 2015, Health technology assessment.
[4] J Karnon,et al. Selecting a decision model for economic evaluation: a case study and review , 1998, Health care management science.
[5] Nicholas R Latimer,et al. Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.
[6] M. Charokopou,et al. Lacosamide as a first-line treatment option in focal epilepsy: a cost-utility analysis for the Greek healthcare system , 2019, Journal of medical economics.
[7] M. Hoogendoorn,et al. Broadening the Perspective of Cost-Effectiveness Modeling in Chronic Obstructive Pulmonary Disease: A New Patient-Level Simulation Model Suitable to Evaluate Stratified Medicine. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[8] Mark Stevenson,et al. Thrombophilia testing in people with venous thromboembolism: systematic review and cost-effectiveness analysis. , 2009, Health technology assessment.
[9] Deirdre Mladsi,et al. The faces of personalized medicine: a framework for understanding its meaning and scope. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[10] B. Celli,et al. Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trial. , 2013, Chest.
[11] M G Myriam Hunink,et al. Uncertainty and Patient Heterogeneity in Medical Decision Models , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.
[12] S. Chick,et al. A taxonomy of model structures for economic evaluation of health technologies. , 2006, Health economics.
[13] Alexandra G. Smith,et al. A Generic Model for Follicular Lymphoma: Predicting Cost, Life Expectancy, and Quality-Adjusted-Life-Year Using UK Population–Based Observational Data☆ , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[14] J. Hay,et al. Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States , 2018, The Annals of pharmacotherapy.
[15] S. McGhee,et al. Cost-effectiveness of a primary care multidisciplinary Risk Assessment and Management Program for patients with diabetes mellitus (RAMP-DM) over lifetime , 2018, Endocrine.
[16] G. Pledger,et al. Tiotropium Respimat Inhaler and the Risk of Death in COPD , 2014 .
[17] K. Boye,et al. The Prime Diabetes Model: Novel Methods for Estimating Long-Term Clinical and Cost Outcomes in Type 1 Diabetes Mellitus. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[18] N. Adlard,et al. When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing–remitting multiple sclerosis , 2018, Journal of medical economics.
[19] U. Siebert,et al. Cost-Effectiveness Models in Breast Cancer Screening in the General Population: A Systematic Review , 2017, Applied Health Economics and Health Policy.
[20] Javier Mar,et al. Economic Evaluation of an Integrated Health and Social Care Program for Heart Failure Through 2 Different Modeling Techniques , 2018, Health services research and managerial epidemiology.
[21] Jeffrey D. Miller,et al. Current challenges in health economic modeling of cancer therapies: a research inquiry. , 2014, American health & drug benefits.
[22] M. Rutten-van Mölken,et al. Not Simply More of the Same , 2014, Medical decision making : an international journal of the Society for Medical Decision Making.
[23] J. Caro,et al. Modeling Using Discrete Event Simulation , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.
[24] Maarten J. IJzerman,et al. Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients. , 2018, Cancer epidemiology.
[25] Uwe Siebert,et al. Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[26] H. Watz,et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4) , 2015, European Respiratory Journal.
[27] B. ó Hartaigh,et al. Evaluating Cost-Effectiveness Models for Pharmacologic Interventions in Adults with Heart Failure: A Systematic Literature Review , 2018, PharmacoEconomics.
[28] Martin Henriksson,et al. A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus , 2016, PharmacoEconomics.
[29] Hendrik Koffijberg,et al. A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level models , 2017, Expert review of pharmacoeconomics & outcomes research.
[30] G. Pledger,et al. Tiotropium Respimat inhaler and the risk of death in COPD. , 2013, The New England journal of medicine.
[31] Mark Stevenson,et al. NICE DSU Technical Support Document 15: Cost-Effectiveness Modelling Using Patient-Level Simulation , 2014 .
[32] Jörgen Möller,et al. Discrete event simulation: the preferred technique for health economic evaluations? , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[33] D. Sin,et al. A Systematic Review of Health Economics Simulation Models of Chronic Obstructive Pulmonary Disease. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[34] M. Decramer,et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.
[35] J. McMurray,et al. Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms , 2014, Heart.
[36] M. Atkins,et al. Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma. , 2019, Immunotherapy.
[37] David Turner,et al. Barriers and Facilitators to Model Replication Within Health Economics. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[38] J. Caro,et al. Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial. , 2005, Journal of cardiac failure.
[39] Javier Mar,et al. Probabilistic cost-utility analysis and expected value of perfect information for the Oncotype multigenic test: a discrete event simulation model. , 2018, Gaceta sanitaria.
[40] P. McEwan,et al. Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK , 2007 .
[41] M. Atkins,et al. Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis. , 2018, Immunotherapy.
[42] James E. Stahl,et al. Pharmacoeconomics 2008; 26 (2): 131-148 , 2012 .
[43] H. Lemij,et al. Surveillance for ocular hypertension: an evidence synthesis and economic evaluation. , 2012, Health technology assessment.
[44] Jonathan Karnon,et al. Model Parameter Estimation and Uncertainty: a Report of the Ispor-smdm Modeling Good Research Practices Task Force-6 Background to the Task Forcemodel-parameter-estimation-and- Uncertainty-analysis.asp). a Summary of These Articles Was Pre- Sented at a Plenary Session at the Ispor 16th Annual Intern , 2022 .